Auteurs

Matthew Royle, Ph.D.

Associé

Read More

Dr. Nora E. Wessendorf, LL.M. (Washington)

Salary Partner

Read More
Auteurs

Matthew Royle, Ph.D.

Associé

Read More

Dr. Nora E. Wessendorf, LL.M. (Washington)

Salary Partner

Read More

25 novembre 2020 | 59:21

Biologics and biosimilars litigation update

Catch up on the third and final webinar in our 2020 series on decisions in the United States and Europe impacting biologics and biosimilars.

Many of the top-selling drugs worldwide are biologics and several companies are seeking to produce biosimilars to compete in these lucrative markets. However, companies continue to face a great deal of uncertainty due to unresolved legal questions involving the governing statutes and patent rights.

Session 3 focuses on recent key developments in the United States and Europe, including:

  • Recent decisions and developments in the United States which may impact biologics and biosimilars, including Arthrex v Smith & Nephew, AAM v Becerra, and GSK v Teva.
  • Recent decisions and developments in Europe, including the Santen CJEU decision, enforcement of personalised medicine claims, and the UK’s guidelines for biosimilars post Brexit. 
Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Sciences de la vie et Santé

Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents

27 juillet 2020
QUICK READ

par plusieurs auteurs

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Everything biologic and biosimilar in-house counsel need to know about COVID-19

29 avril 2020

par plusieurs auteurs

Cliquer ici pour en savoir plus
Sciences de la vie et Santé

Biosimilars – The economics of biosimilars: Market access, pricing and legal considerations

17 décembre 2019

par Matthew Royle, Ph.D.

Cliquer ici pour en savoir plus

Événements connexes